Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 5/20 | 0.44 |
| ▸ | ACE | P12821 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 3/20 | 0.38 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.38 |
| ▸ | SUCNR1 | Q9BXA5 | 1/20 | 0.38 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.38 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.38 |
| ▸ | BLM | P54132 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | ANPEP | P15144 | 3/20 | 0.37 |
| ▸ | ENPEP | Q07075 | 3/20 | 0.37 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.34 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12092215 | 1.00 | FOLH1 (0.44) | FOLH1ACELMNAALKBH5SUCNR1 | |
| SCHEMBL30505307 | 1.00 | FOLH1 (0.44) | FOLH1ACELMNAALKBH5SUCNR1 | |
| SCHEMBL40095 | 1.00 | FOLH1 (0.44) | FOLH1ACELMNAALKBH5SUCNR1 | |
| SCHEMBL13907082 | 1.00 | FOLH1 (0.44) | FOLH1ACELMNAALKBH5SUCNR1 | |
| SCHEMBL6366305 | 0.97 | — | — | |
| SCHEMBL15907907 | 0.88 | FOLH1 (0.42) | FOLH1ACELMNAALKBH5SUCNR1 | |
| Mercaptopropionic Acid SCHEMBL331255 | 0.87 | ACE (0.50) | FOLH1ACELMNAALKBH5SUCNR1 | |
| SCHEMBL1766170 | 0.87 | LMNA (0.50) | LMNAALKBH5SUCNR1EGLN1PMP22 | |
| SCHEMBL351356 | 0.87 | LMNA (0.50) | LMNAALKBH5SUCNR1EGLN1PMP22 | |
| SCHEMBL1766162 | 0.87 | LMNA (0.50) | LMNAALKBH5SUCNR1EGLN1PMP22 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250099600-A1 | Active Metabolites of Kinesin Spindle Protein Inhibitor Conjugates | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2025-03-27 | — | — | US | disclosed |
| US-12144865-B2 | Antibody drug conjugates with enzymatically cleavable groups | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2024-11-19 | — | — | US | disclosed |
| US-11806404-B2 | Site specific homogeneous with KSP inhibitors | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2023-11-07 | — | — | US | disclosed |
| US-20230204570-A1 | SENSOR DEVICE FOR ELECTROCHEMICAL ANALYSIS OF BIOLOGICAL SAMPLES | FOOTHOLD LABS INC. | 2023-06-29 | — | — | US | disclosed |
| US-11685714-B2 | Prodrugs of cytotoxic active agents having enzymatically cleavable groups | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2023-06-27 | — | — | US | disclosed |
| US-20230039341-A1 | ANTIBODY DRUG CONJUGATES (ADCS) AND ANTIBODY PRODRUG CONJUGATES (APDCS) WITH ENZYMATICALLY CLEAVABLE GROUPS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2023-02-09 | — | — | US | disclosed |
| CN-114917361-A | Antibody Drug Conjugates (ADC) and antibody prodrug conjugates (APDC) with enzyme cleavable groups | 拜耳医药股份有限公司 | 2022-08-19 | — | — | CN | disclosed |
| US-11123439-B2 | Antibody drug conjugates (ADCS) and antibody prodrug conjugates (APDCS) with enzymatically cleavable groups | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2021-09-21 | — | — | US | disclosed |
| US-20210252161-A1 | SITE SPECIFIC HOMOGENEOUS WITH KSP INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2021-08-19 | — | — | US | disclosed |
| US-10973923-B2 | Site specific homogeneous with KSP inhibitors | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2021-04-13 | — | — | US | disclosed |
| US-20130336920-A1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | ARDELYX, INC. (US) | 2013-12-19 | — | — | US | disclosed |
| WO-2013109939-A1 | METHODS OF MAKING AND USING NANOSTRUCTURES | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2013-07-25 | — | — | WO | disclosed |
| EP-2590656-A2 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | Ardelyx, Inc. (US) | 2013-05-15 | — | — | EP | disclosed |
| EP-2591354-A1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | Ardelyx, Inc. (US) | 2013-05-15 | — | — | EP | disclosed |
| WO-2012054110-A2 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | ARDELYX, INC. (US) | 2012-04-26 | — | — | WO | disclosed |
| WO-2012006475-A1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | ARDELYX, INC. (US) | 2012-01-12 | — | — | WO | disclosed |
| US-20110124844-A1 | Selective and Specific Preparation of Discrete Peg Compounds | AUDAX PRIVATE DEBT LLC, AS AGENT | 2011-05-26 | — | — | US | disclosed |
| US-20110124844-A1 | Selective and Specific Preparation of Discrete Peg Compounds | AUDAX PRIVATE DEBT LLC, AS AGENT | 2011-05-26 | — | — | US | disclosed |
| US-7888536-B2 | Selective and specific preparation of discrete PEG compounds | QUANTA BIODESIGN, LTD. (US) | 2011-02-15 | — | — | US | disclosed |
| US-7888536-B2 | Selective and specific preparation of discrete PEG compounds | QUANTA BIODESIGN, LTD. (US) | 2011-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11123439-B2 | Antibody drug conjugates (ADCS) and antibody prodrug conjugates (APDCS) with enzymatically cleavable groups | KIFC1, KIF2C, KIF5B | FOLH1 1021/4885ACE 1240/4885LMNA 2730/4885 |
| US-11806404-B2 | Site specific homogeneous with KSP inhibitors | KIF5B, KIF15, KIF2C | FOLH1 690/4885ACE 3684/4885LMNA 3368/4885 |
| US-11685714-B2 | Prodrugs of cytotoxic active agents having enzymatically cleavable groups | BUB1B, KIF5B, TK1 | FOLH1 317/4885ACE 1187/4885LMNA 552/4885 |
| US-20110124844-A1 | Selective and Specific Preparation of Discrete Peg Compounds | PARG, GNE, PAM | FOLH1 2375/4885ACE 2382/4885LMNA 1964/4885 |
| US-10973923-B2 | Site specific homogeneous with KSP inhibitors | KIF5B, KIF15, KIF2C | FOLH1 690/4885ACE 3684/4885LMNA 3368/4885 |
| US-20210252161-A1 | SITE SPECIFIC HOMOGENEOUS WITH KSP INHIBITORS | KIF5B, KIF15, KIF2C | FOLH1 690/4885ACE 3684/4885LMNA 3368/4885 |
| US-20130336920-A1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | SLC34A2, SLC34A1, SLC10A2 | FOLH1 562/4885ACE 1160/4885LMNA 2948/4885 |
| US-20250099600-A1 | Active Metabolites of Kinesin Spindle Protein Inhibitor Conjugates | KIF18B, KIF18A, KIF5B | FOLH1 1968/4885ACE 4463/4885LMNA 2715/4885 |
| US-12144865-B2 | Antibody drug conjugates with enzymatically cleavable groups | KIFC1, KIF2C, KIF5B | FOLH1 577/4885ACE 1563/4885LMNA 2581/4885 |
| US-20230039341-A1 | ANTIBODY DRUG CONJUGATES (ADCS) AND ANTIBODY PRODRUG CONJUGATES (APDCS) WITH ENZYMATICALLY CLEAVABLE GROUPS | KIFC1, KIF2C, KIF5B | FOLH1 1021/4885ACE 1240/4885LMNA 2730/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.